Top

Published in:

01-01-2012 | Research Paper

CD44 is a biomarker associated with human prostate cancer radiation sensitivity

Authors: WeiWei Xiao, Peter H. Graham, Carl A. Power, Jingli Hao, John H. Kearsley, Yong Li

Published in: Clinical & Experimental Metastasis | Issue 1/2012

Abstract

CD44 plays an important role in cancer metastasis, chemotherapy, and radiation resistance. The present study investigated the relationship of CD44 expression and radioresistance, and the potential mechanisms of CD44 in radiosensitivity using prostate cancer (CaP) cell lines. CD44 was knocked down in three CaP cell lines (PC-3, PC-3M-luc, and LNCaP) using small interfering RNA (siRNA) and clonogenic survival fractions after single dose irradiation were compared before and after CD44 knocking down (KD). The effect of radiation on cell cycle distribution was examined by flow cytometry and the cell cycle-related protein levels of phospho-Chk1 and phospho-Chk2 were ascertained by Western blotting. The expression of the DNA double strand break (DSB) marker-γH2AX was also quantified by immunofluorescence staining. Our results indicate that the down-regulation of CD44 enhanced radiosensitivity in PC-3, PC-3M-luc, and LNCaP CaP cells, the sensitizing enhancement ratio for these cell lines was 2.3, 1.3, and 1.5, respectively and that the delay of DNA DSB repair in low CD44-expressing KD CaP cells correlated with ineffective cell cycle arrest and the delayed phosphorylation of Chk1 and Chk2. These findings suggest that CD44 may be a valuable biomarker and a predictor of radiosensitivity in CaP treatment.

Sandler HM, Mirhadi AJ (2009) Radical radiotherapy for prostate cancer is the ‘only way to go’. Oncology (Williston Park) 23:840–843

Goldner G, Dimopoulos J, Kirisits C, Pötter R (2009) Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy. Strahlenther Onkol 185:438–445PubMedCrossRef

Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A (2011) Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 79:1310–1317PubMedCrossRef

Zapatero A, García-Vicente F, Martín de Vidales C, Cruz Conde A, Ibáñez Y, Fernández I, Rabadán M (2010) Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?. Int J Radiat Oncol Biol Phys 2010. doi:10.1016/j.ijrobp.2010.07.1975

Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A (2007) What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 68:682–689PubMedCrossRef

Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD, Rossi CJ (2010) Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II Study 03–12. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2010.06.047

Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4:33–45PubMedCrossRef

Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV (2008) Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semi Cancer Biol 18:260–267CrossRef

Bourguignon LY, Peyrollier K, Xia W, Gilad E (2008) Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283:17635–17651PubMedCrossRef

10.

Hao JL, Cozzi PJ, Khatri A, Power CA, Li Y (2010) EMMPRIN/CD147 and CD44 are potential therapeutic targets for metastatic prostate cancer. Curr Cancer Drug Targ 20:287–306CrossRef

11.

Hao JL, Chen H, Madigan MC, Cozzi PJ, Beretov J, Xiao W, Delprado WJ, Russell PJ, Li Y (2010) Co-expression of CD147 (EMMPRIN), CD44v3–10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer 103:1008–1018PubMedCrossRef

12.

de Jong MC, Pramana J, van der Wal JE, Lacko M, Peutz-Kootstra CJ, de Jong JM, Takes RP, Kaanders JH, van der Laan BF, Wachters J, Jansen JC, Rasch CR, van Velthuysen ML, Grénman R, Hoebers FJ, Schuuring E, van den Brekel MW, Begg AC (2010) CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res 16:5329–5338PubMedCrossRef

13.

Omara-Opyene AL, Qiu J, Shah GV, Iczkowski KA (2004) Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest 84:894–907PubMedCrossRef

14.

Gao AC, Lou W, Sleeman JP, Isaacs JT (1998) Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res 58:2350–2352PubMed

15.

Yang K, Tang Y, Habermehl GK, Iczkowski KA (2010) Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity. BMC Cancer 10:16PubMedCrossRef

16.

Chen H, Hao J, Wang L, Li Y (2009) Coexpression of invasive markers (uPA, CD44) and multiple drug resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101:432–440PubMedCrossRef

17.

Fertil B, Dertinger H, Courdi A, Malaise EP (1984) Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 99:73–84PubMedCrossRef

18.

Zhang X, Yang H, Gu K, Chen J, Rui M, Jiang GL (2011) In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizer. Int J Nanomedicine 6:437–444PubMedCrossRef

19.

Kim IA, Kim JH, Shin JH, Kim IH, Kim JS, Wu HG, Chie EK, Kim YH, Kim BK, Hong S, Park SW, Ha SW, Park CI (2005) A histone deacetylase inhibitor, trichostatin A, enhances radiosensitivity by abrogating G2/M arrest in human carcinoma cells. Cancer Res Treat 37:122–128PubMedCrossRef

20.

Supiot S, Hill RP, Bristow RG (2008) Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 7:993–999PubMedCrossRef

21.

Schmidberger H, Rave-Fränk M, Lehmann J, Schweinfurth S, Pradier O, Hess CF (1999) Radiosensitizing effect of natural and recombinant beta-interferons in a human lung carcinoma in vitro. J Cancer Res Clin Oncol 125:350–356PubMedCrossRef

22.

Hofstetter B, Niemierko A, Forrer C, Benhattar J, Albertini V, Pruschy M, Bosman FT, Catapano CV, Ciernik IF (2010) Impact of genomic methylation on radiation sensitivity of colorectal carcinoma. Int J Radiat Oncol Biol Phys 76:1512–1519PubMedCrossRef

23.

Kaufmann WK, Paules RS (1996) DNA damage and cell cycle checkpoints. FASEB J 10:238–247PubMed

24.

Fingert HJ, Chang JD, Pardee AB (1986) Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. Cancer Res 46:2463–2467PubMed

25.

Harper LJ, Costea DE, Gammon L, Fazil B, Biddle A, Mackenzie IC (2010) Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance. BMC Cancer 10:166PubMedCrossRef

26.

Sak A, Stuschke M (2010) Use of γH2AX and other biomarkers of double-strand breaks during radiotherapy. Semin Radiat Oncol 20:223–231PubMedCrossRef

27.

Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8:806–823PubMedCrossRef

28.

Greaves M (2010) Cancer stem cells: back to Darwin? Semin Cancer Biol 20:65–70PubMedCrossRef

29.

Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25:1696–1708PubMedCrossRef

30.

Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL (2008) CD44+ CD24(−) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 98:756–765PubMedCrossRef

31.

Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760PubMedCrossRef

32.

Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(−/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98:1777–1785PubMedCrossRef

33.

Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM (2007) WNT/beta-catenin mediatesradiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 104:618–623PubMedCrossRef

34.

Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780–783PubMedCrossRef

35.

Lagadec C, Vlashi E, Della Donna L, Meng Y, Dekmezian C, Kim K, Pajonk F (2010) Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res 12:R13PubMedCrossRef

36.

Zöller M (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11:254–267PubMedCrossRef

37.

Maula SM, Luukkaa M, Grénman R, Jackson D, Jalkanen S, Ristamäki R (2003) Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 63:1920–1926PubMed

38.

Lin JT, Chang TH, Chang CS, Wang WH, Su BW, Lee KD, Chang PJ (2010) Prognostic value of pretreatment CD44 mRNA in peripheral blood of patients with locally advanced head and neck cancer. Oral Oncol 46:e29–e33PubMedCrossRef

Title: CD44 is a biomarker associated with human prostate cancer radiation sensitivity
Authors: WeiWei Xiao
Peter H. Graham
Carl A. Power
Jingli Hao
John H. Kearsley
Yong Li
Publication date: 01-01-2012
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 1/2012
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-011-9423-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2α and survival

Down-regulation of matrix metalloproteinase-7 inhibits metastasis of human anaplastic thyroid cancer cell line

Functional mutation analysis of EGFR family genes and corresponding lymph node metastases in head and neck squamous cell carcinoma

CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion

Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI

Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance

Keynote webinar | Spotlight on antibody–drug conjugates in cancer